Alimentary TractVaccination coverage of children with inflammatory bowel disease after an awareness campaign on the risk of infection
Introduction
The use of immunosuppressive therapy such as corticosteroids, antimetabolites (6-mercaptopurine [6MP], methotrexate, and azathioprine), and biologics has led to marked improvements for patients (children and adults) with inflammatory bowel disease (IBD); however, at the same time, these therapies increase the risk of opportunistic infections [1], [2], [3], [4]. These infections can be prevented through vaccination. This is why specific recommendations have been implemented in addition to the usual recommendations. Patients must be brought up-to-date with scheduled vaccinations as soon as possible in the course of their disease (ideally from diagnosis) in order to achieve a better immune response and be able to administer live attenuated vaccines, which will be contraindicated if immunosuppressive therapy is subsequently administered [1], [4], [5]. The recommended vaccines are those of the vaccination schedule (for France) plus the influenza and pneumococcal vaccines [6], [7].
Several studies have shown that the level of vaccination coverage for IBD patients is insufficient [8], [9]. A previous study involving 165 children with IBD, conducted between May and November 2011 at 11 hospitals in western France, showed that vaccination coverage in this population was largely insufficient [8]. The primary cause seems to be the lack of information provided to patients and to doctors responsible for vaccination. In addition to vaccine catch-up, prevention must also be implemented [8], [10], [11].
The aim of our study was to evaluate vaccination coverage among children with IBD following an awareness campaign about the infection risk to their family and their GP. To this aim, a letter was sent to patients of a previously evaluated cohort [8] and to their GP, in order to raise awareness about the vaccination schedule.
Section snippets
Materials and methods
The dosing schedule recommended to patients, their family, and their doctor was the one published by the French High Council for Public Health (HCSP) in February 2012 [6].
All patients with known vaccination coverage subsequent to data collection in 9 hospitals in western France [8] were included in this prospective study conducted from March 6, 2013 to January 31, 2014. The awareness-raising campaign implemented in this study consisted of providing information about the infection risk and the
Results
The campaign letters were sent out to 105 includable patients and their GPs. Among these, 2 refused to participate in the study and 11 were not subsequently seen. Hence, 92 patients were included, giving a response rate of 88%.
Discussion
Clear recommendations exist for evaluating IBD patients before initiating treatment, especially with anti-TNF agents, and bringing them up-to-date with vaccinations [1], [6], [7], [12], [13]. Although such patients, who are currently immunosuppressed or likely to be immunosuppressed in the future, are at a higher risk of infection, particularly opportunistic infections [1], [2], [3], [4], several studies have shown that doctors and patients are not provided information [8], [9] about the
Conflict of interest
None declared.
References (22)
- et al.
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
Journal of Crohn's and Colitis
(2014) - et al.
Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary
Journal of Pediatric Gastroenterology and Nutrition
(2012) - et al.
Opportunistic infections due to inflammatory bowel disease therapy
Inflammatory Bowel Diseases
(2014) - et al.
Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations
Journal of Pediatric Gastroenterology and Nutrition
(2012) - et al.
Vaccination of patients with inflammatory bowel disease. Practical recommendations
Revista Espanola de Enfermedades Digestivas
(2013) - et al.
Vaccinations in patients with immune-mediated inflammatory diseases
Rheumatology
(2010) - et al.
Vaccination and infection prevention in inflammatory bowel disease
F1000 Medicine Reports
(2010) Avis relatif aux recommandations vaccinales spécifiques des personnes immunodéprimées ou aspléniques
(2012)- et al.
Immunization status in children with inflammatory bowel disease
European Journal of Pediatrics
(2014) - et al.
Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement
Inflammatory Bowel Diseases
(2014)
Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease
Journal of Crohn's and Colitis
Cited by (13)
A preliminary prospective study: Could the labeling of a health-care message on a consumer product limit forgetfulness in parents confronted with immunization?
2019, Archives de PediatrieCitation Excerpt :Reducing fear and promoting the benefits of vaccination is complex as the prevalence of certain diseases covered by vaccines is declining [11,14]. Many other teams have also proposed solutions to combat parental hesitancy concerning immunization [15,26,27]. For Nahon-Serfaty et al. [28], vaccination involves public health, political, economic, and marketing problems equally, for which communication is essential.
Vaccination coverage in children with juvenile idiopathic arthritis, inflammatory bowel diseases, and healthy peers: Cross-sectional electronic survey data
2023, World Journal of Clinical PediatricsA single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease
2022, Therapeutic Advances in Gastroenterology